NASDAQ:AVDL - Avadel Pharmaceuticals Stock Price, Forecast & News

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Avadel Pharmaceuticals declared that its Board of Directors has approved a share repurchase plan on Wednesday, March 28th 2018, which permits the company to repurchase $7,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 2.7% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's board of directors believes its stock is undervalued.

Avadel Pharmaceuticals PLC (NASDAQ:AVDL) released its earnings results on Tuesday, November, 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.03. The firm earned $14.23 million during the quarter. Avadel Pharmaceuticals had a negative net margin of 136.46% and a negative return on equity of 608.01%. View Avadel Pharmaceuticals' Earnings History.

Avadel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Avadel Pharmaceuticals.

Avadel Pharmaceuticals updated its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $$55 million, compared to the consensus revenue estimate of $$50.99 million.

3 brokers have issued 1-year price objectives for Avadel Pharmaceuticals' shares. Their forecasts range from $6.00 to $15.00. On average, they expect Avadel Pharmaceuticals' stock price to reach $9.00 in the next year. This suggests a possible upside of 27.1% from the stock's current price. View Analyst Price Targets for Avadel Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avadel Pharmaceuticals.

Media stories about AVDL stock have trended extremely negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Avadel Pharmaceuticals earned a news sentiment score of -4.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Avadel Pharmaceuticals.

Some companies that are related to Avadel Pharmaceuticals include Enanta Pharmaceuticals (ENTA), Portola Pharmaceuticals (PTLA), Opko Health (OPK), Myovant Sciences (MYOV), Karyopharm Therapeutics (KPTI), Dermira (DERM), Odonate Therapeutics (ODT), Kiniksa Pharmaceuticals (KNSA), Applied Therapeutics (APLT), Gossamer Bio (GOSS), Cytokinetics (CYTK), Achillion Pharmaceuticals (ACHN), Stoke Therapeutics (STOK), I-Mab (ARQT) and Phathom Pharmaceuticals (PHAT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Chaarat Gold (CGH), Associated British Foods (ABF), AMC Entertainment (AMC), Ciena (CIEN), Apollo Global Management (APO), First Data (FDC) and Cypress Semiconductor (CY).

Avadel Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Brandes Investment Partners LP (9.75%), Broadfin Capital LLC (2.75%), Renaissance Technologies LLC (2.28%), Iridian Asset Management LLC CT (0.83%), Keel Point LLC (0.11%) and Perceptive Advisors LLC (0.02%). Company insiders that own Avadel Pharmaceuticals stock include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, James E Flynn, Michael S Anderson and Sandra L Hatten. View Institutional Ownership Trends for Avadel Pharmaceuticals.

AVDL stock was sold by a variety of institutional investors in the last quarter, including Brandes Investment Partners LP and Broadfin Capital LLC. View Insider Buying and Selling for Avadel Pharmaceuticals.

AVDL stock was purchased by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, Keel Point LLC, Renaissance Technologies LLC, Perceptive Advisors LLC, Perceptive Advisors LLC, Carmichael Hill & Associates Inc., Steward Partners Investment Advisory LLC and UBS Group AG. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Eric J Ende, Geoffrey Michael Glass, Greg J Divis and Michael S Anderson. View Insider Buying and Selling for Avadel Pharmaceuticals.

Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AVDL stock can currently be purchased for approximately $7.08.

Avadel Pharmaceuticals has a market capitalization of $265.15 million and generates $103.27 million in revenue each year. The company earns $-95,300,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Avadel Pharmaceuticals employs 144 workers across the globe.View Additional Information About Avadel Pharmaceuticals.

The official website for Avadel Pharmaceuticals is http://www.avadel.com/.

Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 353-1485-1200 or via email at [email protected]